Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001179110-20-007218
Filing Date
2020-06-11
Accepted
2020-06-11 07:54:59
Documents
1
Period of Report
2020-06-10

Document Format Files

Seq Description Document Type Size
1 FORM 4 - edgar.html 4  
1 FORM 4 - edgar.xml 4 3118
  Complete submission text file 0001179110-20-007218.txt   4716
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Issuer) CIK: 0000744218 (see all company filings)

EIN.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2835 In Vitro & In Vivo Diagnostic Substances

Mailing Address C/O CELLDEX THERAPEUTICS, INC. 53 FRONTAGE ROAD, SUITE 220 HAMPTON NJ 08827
Business Address
Cavanaugh Sarah (Reporting) CIK: 0001709113 (see all company filings)

Type: 4 | Act: 34 | File No.: 000-15006 | Film No.: 20956211